Caladrius Biosciences to Participate at Upcoming April Conferences

BASKING RIDGE, N.J., April 09, 2018 -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces today that Douglas Losordo, M.D., FACC, FAHA, Senior Vice President of Clinical Medical and Regulatory Affairs and Chief Medical Officer, will participate at the following conferences in April:

GTCbio 15th Stem Cell Summit

• Session: Advances in Adult Stem Cell Research
• Title: Recent Breakthroughs with CD34+ Cell Therapy in Cardiovascular Disease: Insights from Clinical Trials in >700 Patients
• Date and Time: Thursday, April 12, 2018 at 10:55am EST
• Location: Hyatt Regency Boston Hotel, Boston, MA

In addition, Dr. Losordo will act as moderator for the panels entitled “Regulatory Challenges in Cell Therapy” and “Revolution in Immunotherapy.”  For more information, please visit www.gtcbio.com/conferences/stem-cell-summit.  

Fourth International Vatican Conference

• First Session: Partnerships to Accelerate Discovery for New-Onset Type 1 Diabetes
  • Date and Time: Thursday, April 26, 2018 at 6:05pm CEST
• Second Session: The Pharmacy of the Future – Cells Not Pills
  • Date and Time: Friday, April 27, 2018 at 8:25am CEST
• Location: Aula Nuova del Sinodo, Vatican City, Rome
• Website: vaticanconference2018.com

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications. The Company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes, in an ongoing Phase 2 trial. CLBS14, CD34 cell therapy intended as a treatment for coronary microvascular dysfunction and refractory angina, is Caladrius’ proprietary and patent protected formulation of CD34 cells designed specifically to enhance the potency of the CD34 cells for repair and regeneration of cardiovascular tissue. Its companion product, CLBS12, is formulated specifically for intramuscular administration for the treatment of lower extremity ischemia. A phase 2 study of CLBS12 as a treatment for critical limb ischemia is enrolling in Japan, a successful outcome of which will qualify the program for consideration of early conditional approval based on discussions with the Japanese regulatory authorities as provided for under Japan’s progressive regenerative medicine regulations.   For more information about Caladrius please visit www.caladrius.com.

Contacts:
Caladrius Biosciences, Inc.
John Menditto
Executive Director, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: [email protected]

LHA Investor Relations
Miriam Weber Miller
Senior Vice President
Phone: +1-212-838-3777
Email: [email protected]